ArticleMaterials today. Bio2026
A natural remedy: Kidney-targeting nanoplatform for photoacoustic imaging-guided three-in-one theranostics of rhabdomyolysis-induced acute kidney injury.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high lethality of acute kidney injury (AKI) and the lack of safe and effective theranostic strategies pose significant challenges in clinical practice. Natural remedies are emerging as a promising alternative approach to alleviate AKI. Herein, we develop a novel kidney-targeting nanoplatform, MNPC@SC, which is engineered for pH-responsive drug release. Concretely, MNPC@SC encapsulates the natural bioactive ingredients curcumin (Cur) and melanin nanoparticles (MNPs) within a sialic acid (SA)-crosslinked chitosan shell, ensuring active renal targeting and optimal drug delivery via the electrostatic interactions between SA and chitosan. The acidic microenvironment of AKI triggers the responsive degradation of the MNPC@SC, further enabling the controlled release of MNPs and Cur specifically within the injured kidneys. The released MNPs and Cur achieve highly effective anti-inflammatory, anti-apoptotic, and anti-oxidant treatment, while MNPs serve as a contrast agent for photoacoustic (PA) imaging to self-monitor the drug distribution. To sum up, this pH-responsive targeting nanoplatform, MNPC@SC, as a new natural remedy, is believed to achieve efficient PA imaging-guided three-in-one synergistic therapy for AKI, which may pave the way for exploring highly efficient and safe theranostic strategies for severe kidney injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.